Search for: "Ambry Genetics"
Results 1 - 20
of 41
Sorted by Relevance
|
Sort by Date
9 Jul 2013, 9:59 pm
Ambry Genetics was one of the first companies to announce that it would provide genetic diagnostic testing for the BRCA 1 and BRCA 2 genes on the day the U.S. [read post]
27 Aug 2013, 9:53 pm
The amici brief was submitted in support of Ambry Genetics and Gene by Gene, which have opposed Myriad's motion for a preliminary injunction. [read post]
7 Aug 2013, 9:59 pm
Procedurally, Ambry raised no challenge to jurisdiction or venue, but denied that the named plaintiffs are the owners or co-owners of the asserted patents, and admitted only that it provides genetic diagnostic testing services... [read post]
11 Jul 2013, 1:00 am
On July 9, 2013, Myriad Genetics, Inc. brought suit against Ambry Genetics Corporation, alleging that Ambry is infringing ten (10) patents by offering breast cancer genetic testing for the BRCA1 and/or BRCA2 mutations associated with aggressive forms of breast and ovarian cancer. [read post]
10 Jul 2013, 9:31 pm
Noonan -- A day after Myriad Genetics sued Ambry Genetics for patent infringement, the company filed suit in the District of Utah, Central Divisions against Gene by Gene Ltd. [read post]
9 Oct 2013, 8:12 pm
Noonan -- Not to be outdone by defendants Ambry Genetics and Gene-by-Gene's 109-page brief in opposition to Myriad's Preliminary Injunction Motion, Myriad has now filed a Reply Brief weighing in at 140 pages (page limits in briefs seemingly unknown in the District of Utah). [read post]
28 Aug 2013, 8:57 pm
Ambry Genetics case, Myriad argues that this legal precedent, as well as the principles first enunciated... [read post]
20 Jul 2013, 7:27 pm
As has been widely reported, hot on the heels of its ‘loss’ at the US Supreme Court Myriad Genetics has sued Ambry Genetics for infringing 10 patents covering genetic testing for BRCA1 and BRCA2 genes linked to breast and ovarian cancer. [read post]
23 Oct 2013, 9:56 pm
Noonan -- On July 19th, Myriad Genetics amended its complaint against Ambry Genetics to include claims to its patents relating to colon cancer predictive genetic diagnostic testing (amended complaint). [read post]
18 Jul 2013, 12:00 am
One of the most interesting arguments that Myriad made in its Motion for Preliminary Injunctive Relief in its infringement action against Ambry Genetics Corporation relates to the database of genetic information that Myriad has developed over its years of conducting BRCA1 and BRCA2 genetic... [read post]
21 Oct 2013, 8:54 pm
The complaint is similar to Myriad's complaints against Ambry Genetics and Gene-by-Gene, but this time Myriad has added infringement allegations relating to its mutY homolog (MUTYH)... [read post]
30 Jul 2013, 9:20 pm
Noonan -- Earlier this month, Myriad Genetics filed patent infringement lawsuits against Ambry Genetics (on July 9th) and Gene-by-Gene (on July 10th). [read post]
27 Jan 2015, 9:59 pm
On Myriad's motion, the Judicial Panel on Multidistrict Litigation consolidated five of these actions (involving Ambry Genetics, GeneDx, Quest... [read post]
19 Sep 2013, 9:35 pm
Ambry Genetics Corp. and Myriad Genetics v. [read post]
18 Mar 2014, 3:00 am
District Court for the District of Utah denied Myriad’s motion for a preliminary injunction against Ambry Genetics Corp. [read post]
25 Sep 2014, 9:37 am
Ambry Genetics Corp., argument is scheduled for 10:00 am on Monday, October 6th. [read post]
20 Mar 2014, 9:24 pm
Myriad is seeking to have the Court review and reverse the District Court's denial of the company's preliminary jnjunction motion against Ambry Genetics in its on-going (and now consolidated) lawsuit on several claims from Myriad's BRCA gene testing patents. [read post]
9 Jul 2013, 8:37 pm
Ambry Genetics (D. [read post]
12 Mar 2014, 8:02 am
Myriad asked a federal judge in Utah to order one of the laboratories, Ambry Genetics, to stop providing testing of the BRCA genes. [read post]
28 Oct 2013, 9:59 pm
Noonan -- In responding to Myriad Genetics' complaint for patent infringement, both Ambry Genetics and Gene-by-Gene asserted counterclaims under the Sherman Antitrust Act, predicated on Myriad's filing its patent infringement lawsuit. [read post]
